Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.46 |
| ▸ | SSTR4 | P31391 | 10/20 | 0.44 |
| ▸ | SSTR1 | P30872 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15677613 | 0.86 | SLC22A12 (0.44) | SLC22A12SSTR4SSTR1ALDH1A1MAPT | |
| SCHEMBL16579444 | 0.84 | ALDH1A1 (0.44) | SLC22A12SSTR4SSTR1ALDH1A1MAPT | |
| SCHEMBL12922790 | 0.83 | MEN1 (0.42) | ALDH1A1SLC6A2 | |
| SCHEMBL19002316 | 0.82 | SSTR4 (0.51) | SLC22A12SSTR4SSTR1 | |
| SCHEMBL30115270 | 0.82 | SMN1; SMN2 (0.39) | SLC22A12SSTR4SSTR1HTR1ASLC6A2 | |
| SCHEMBL29213683 | 0.81 | GAA (0.42) | ALDH1A1ATMSLC6A2SLC6A4 | |
| SCHEMBL30440802 | 0.81 | SLC22A12 (0.55) | SLC22A12ALDH1A1MAPTATMNFE2L2 | |
| SCHEMBL322870 | 0.81 | SLC22A12 (0.55) | SLC22A12ALDH1A1MAPTATMNFE2L2 | |
| SCHEMBL2825181 | 0.80 | KDM4E (0.53) | SSTR4SSTR1ALDH1A1 | |
| SCHEMBL23886163 | 0.80 | SSTR4 (0.49) | SLC22A12SSTR4SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319683-B2 | Azabenzimidazole compounds and pharmaceutical | NIPPON SHINYAKU CO., LTD. (JP) | 2025-06-03 | — | — | US | disclosed |
| CN-112441966-A | Method for producing 2-chloro-3-trifluoromethylpyridine from 2,3, 6-trichloro-5-trifluoromethylpyridine | 山东省农药科学研究院 | 2021-03-05 | — | — | CN | disclosed |
| US-20190055257-A1 | SUBSTITUTED 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-21 | — | — | US | disclosed |
| EP-3233077-A1 | DOPAMINE D2 RECEPTOR LIGANDS | The Broad Institute Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-3004107-B1 | 6,7-DIHYDROPYRAZOLO[1,5-A]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016100940-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-8013001-B2 | Modulators of LXR | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100056582-A1 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| EP-1811845-A4 | SUBSTITUTED BIARYL QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORP (US) | 2009-07-15 | — | — | EP | disclosed |
| US-7482366-B2 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2009-01-27 | — | — | US | disclosed |
| US-20080071084-A1 | Using an alcohol in presence of copper catalyst and ligand | ARCHIMICA GMBH (DE) | 2008-03-20 | — | — | US | disclosed |
| US-20080071084-A1 | Using an alcohol in presence of copper catalyst and ligand | ARCHIMICA GMBH (DE) | 2008-03-20 | — | — | US | disclosed |
| EP-1873136-A1 | Method for manufacturing alkyl and aryl ethers | Archimica GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| EP-1873136-A1 | Method for manufacturing alkyl and aryl ethers | Archimica GmbH (DE) | 2008-01-02 | — | — | EP | disclosed |
| EP-1811845-A2 | SUBSTITUTED BIARYL QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1773337-A2 | MODULATORS OF NUCLEAR RECEPTORS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006042289-A2 | SUBSTITUTED BIARYL QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006025979-A9 | MODULATORS OF NUCLEAR RECEPTORS | EXELIXIS INC (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006025979-A2 | MODULATORS OF NUCLEAR RECEPTORS | EXELIXIS, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| US-20050080111-A1 | Modulators of LXR | X-CEPTOR THERAPEUTICS, INC. (US) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080111-A1 | Modulators of LXR | NR1H2, NR1H3, NR1H4 | SLC22A12 1905/4885SSTR4 1340/4885SSTR1 1114/4885 |
| US-20080071084-A1 | Using an alcohol in presence of copper catalyst and ligand | NR1H3, NR1H2, ADH1A | SLC22A12 2841/4885SSTR4 1924/4885SSTR1 790/4885 |
| US-20190055257-A1 | SUBSTITUTED 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM5, GRM1 | SLC22A12 967/4885SSTR4 1983/4885SSTR1 1111/4885 |
| US-20100056582-A1 | Modulators of LXR | NR1H2, NR1H3, NR1H4 | SLC22A12 1905/4885SSTR4 1340/4885SSTR1 1114/4885 |
| US-12319683-B2 | Azabenzimidazole compounds and pharmaceutical | PAM, CHRM3, AZI2 | SLC22A12 1322/4885SSTR4 1340/4885SSTR1 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.